Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

247323b2-dc45-427e-bc41-c33f2fbbe77b

—

83a747d2-bedf-5bf1-8134-b857237f098a

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
  • TGF_BETA_SIGNALING+0.600
  • ANGIOGENESIS+0.500
  • TNFA_SIGNALING_VIA_NFKB+0.500
  • E2F_TARGETS+0.400
  • G2M_CHECKPOINT+0.400
  • HYPOXIA+0.400
  • IL6_JAK_STAT3_SIGNALING+0.400
  • INFLAMMATORY_RESPONSE+0.400
  • MYC_TARGETS_V1+0.400

Top 10 suppressed

  • BILE_ACID_METABOLISM-0.300
  • INTERFERON_ALPHA_RESPONSE-0.300
  • KRAS_SIGNALING_DN-0.300
  • OXIDATIVE_PHOSPHORYLATION-0.300
  • FATTY_ACID_METABOLISM-0.200
  • PEROXISOME-0.200
  • ADIPOGENESIS-0.100
  • ESTROGEN_RESPONSE_EARLY-0.100
  • ESTROGEN_RESPONSE_LATE-0.100
  • HEME_METABOLISM-0.100

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1SJEPD032038_D1.RNA-Seq
medullo-epn-umap@date-based
EPNSupratentorial EPN0.854
2TCGA-CQ-5326-01A-01R-1873-07
head-neck@1
——0.850
3BS_1AYRM596
medullo-epn-umap@date-based
MedMedulloblastoma0.843
4MDT-AP-2040
medullo-epn-umap@date-based
MedMedulloblastoma0.842
5SRR934963
brain-umap@2
——0.837
6ERR2208969
melanoma-umap@29
——0.837
7BS_MKM0EEN1
brain-umap@2
Diffuse intrinsic pontine glioma—0.829
8SRR934881
brain-umap@2
——0.828
9TCGA-BH-A0AV-01A-31R-A115-07
breast-umap@18
—E0.827
10MDT-AP-0309
medullo-epn-umap@date-based
MedMedulloblastoma0.824

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 31 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.600Inavolisib— uncovered
TGF_BETA_SIGNALING0.600Inavolisib— uncovered
ANGIOGENESIS0.500Remibrutinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.500Inavolisib— uncovered
E2F_TARGETS0.400Inavolisib— uncovered
G2M_CHECKPOINT0.400Inavolisib— uncovered
HYPOXIA0.400Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.400Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.400Idelalisib— uncovered
MYC_TARGETS_V10.400Inavolisib— uncovered
PROTEIN_SECRETION0.400Remibrutinib— uncovered
ALLOGRAFT_REJECTION0.300Idelalisib— uncovered
ANDROGEN_RESPONSE0.300Inavolisib— uncovered
APICAL_JUNCTION0.300Inavolisib— uncovered
COMPLEMENT0.300Inavolisib— uncovered
GLYCOLYSIS0.300Inavolisib— uncovered
KRAS_SIGNALING_UP0.300Inavolisib— uncovered
MITOTIC_SPINDLE0.300Inavolisib— uncovered
MTORC1_SIGNALING0.300Inavolisib— uncovered
PANCREAS_BETA_CELLS0.300Cobimetinib— uncovered